China Biopharmaceutical Says Agreement Covers Six Preclinical Programs
The company said the agreement covers six preclinical asset programs involving antibody-drug conjugates and T-cell engagers.
The company said the agreement covers six preclinical asset programs involving antibody-drug conjugates and T-cell engagers.